Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers warn antipsychotic drug

01.07.2002


Research from Duke University Medical Center suggests there might be a link between at least one drug used to treat schizophrenia and the onset of diabetes, a disease widely recognized as one of the leading causes of death and disability in the U.S.


The drug, olanzapine (trade name Zyprexa), belongs to a relatively new family of medications called atypical antipsychotics, which are used to treat schizophrenia, paranoia and manic-depressive disorders. Other drugs in this class include clozapine, risperidone, quetiapine and ziprasidone.

The researchers found metabolic abnormalities ranging from mild blood sugar problems to diabetic ketoacidosis and coma in patients who had been prescribed olanzapine, most of whom were otherwise not known to be diabetic. Diabetic ketoacidosis (DKA) is a serious condition in which a person experiences an extreme rise in blood glucose level coupled with a severe lack of insulin, which results in symptoms such as nausea, vomiting, stomach pain and rapid breathing. Untreated, DKA can lead to coma and even death.

"While our report does not prove a causal relationship between the drug and diabetes, doctors should be aware of such potentially adverse effects," said P. Murali Doraiswamy, M.D., a psychiatrist at Duke and co-author of the study. "We’ve found cases where patients had some very serious problems associated with olanzapine, and at least 23 of them died."



The findings appear in the July 2, 2002 issue of Pharmacotherapy. The research was self-supported by the authors.

Doraiswamy and Elizabeth A. Koller, M.D., lead author of the study and a medical officer at the FDA, queried the FDA MedWatch Drug Surveillance System, MEDLINE (a biomedical database) and selected abstracts from national psychiatry meetings over a period of eight years and identified 289 cases of diabetes in patients who had been given olanzapine. Of the 289 cases of diabetes linked to the use of olanzapine, 225 were newly diagnosed cases. One hundred patients developed ketosis (a serious complication of diabetes), and 22 people developed pancreatitis, or inflammation of the pancreas, which is a life-threatening condition. There were 23 deaths, including that of a 15-year-old adolescent who died of necrotizing pancreatitis, a condition where the pancreas breaks down and dies. Most cases (71 percent) occurred within six months of starting the drug and many cases were associated with moderate weight gain.

"The average age of adults showing signs of diabetes after taking olanzapine was about 10 years younger than what is generally seen in the community," said Doraiswamy. "The younger age at onset plus the number of serious complications and the improvements reported when the drug was stopped all suggest a link to the disease. However, until we know if there are risk differences among drugs in this class, it is important for physicians to watch all patients receiving this medication for signs of diabetes so that it can be detected quickly and managed."

The study merely suggests an association between the drug and diabetes, said Doraiswamy. Further studies are needed to offer more conclusive evidence of a direct causal relationship. If future studies confirm the findings, he said that perhaps the FDA should consider including a stronger warning label for these drugs.

"The numbers are still sketchy since many adverse reactions are not reported to the FDA and we don’t have a good handle on how many people have actually received these drugs," he cautioned. "Atypical antipsychotics can be life saving medications, but we need to learn more about their long-term side-effects. I think this should be a high priority for investigation."

Doraiswamy was part of a team from Duke that first reported a link between the antipsychotic drug clozapine and the development of diabetes in a 1994 issue of the American Journal of Psychiatry. Last year, Koller reported in the American Journal of Medicine that the FDA had received 384 reports of diabetes associated with the drug clozapine. According to the researchers, many cases of diabetes have also been reported with other antipsychotic drugs.


Doraiswamy has previously received funding and consulting fees from all companies that currently manufacture antipsychotic medications, including Eli Lilly and Company, the manufacturer of Zyprexa.


Tracey Koepke | EurekAlert!

More articles from Health and Medicine:

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

nachricht Alzheimer’s: Cellular Mechanism Provides Explanation Model for Declining Memory Performance
21.09.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

Im Focus: New laser joining technologies at ‘K 2016’ trade fair

Every three years, the plastics industry gathers at K, the international trade fair for plastics and rubber in Düsseldorf. The Fraunhofer Institute for Laser Technology ILT will also be attending again and presenting many innovative technologies, such as for joining plastics and metals using ultrashort pulse lasers. From October 19 to 26, you can find the Fraunhofer ILT at the joint Fraunhofer booth SC01 in Hall 7.

K is the world’s largest trade fair for the plastics and rubber industry. As in previous years, the organizers are expecting 3,000 exhibitors and more than...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

Using mathematical models to understand our brain

16.09.2016 | Event News

 
Latest News

Chains of nanogold – forged with atomic precision

23.09.2016 | Life Sciences

New leukemia treatment offers hope

23.09.2016 | Health and Medicine

Self-assembled nanostructures hit their target

23.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>